Sign in
KALV Stock Price, Chart, Stats & News
KalVista Pharmaceuticals, Inc.
Save
1.44B
Market cap
–
Current P/E
25.45x
Forward P/E
KALV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 68.70% |
Operating margin | -231.07% |
Pretax margin | -227.62% |
Net margin | -222.77% |
Effective tax rate | 2.13% |
ROA | -49.85% |
ROE | -444.41% |
D/E | -99.23x |
Interest coverage ratio | -8.73x |
KALV valuation
P/E | – |
P/S | 13.19x |
P/B | -360.33x |
P/CF | -11.89x |
P/FCF | -12.08x |
P/OCF | -11.89x |
PEG | -0.29x |
EV multiple | -4.40x |
About
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T.
Similar securities
Based on sector and market capitalization
Report issue